Dosing and therapeutic monitoring of phenytoin in young adults after neurotrauma: Are current practices relevant?

Clinical Neuropharmacology

Volumn 30, Issue 6, 2007, Pages 362-369

  Frend, Vivien ^a   Chetty, Manoranjenni ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Head injuries; Neurotrauma; Pharmacokinetic changes; Phenytoin; Therapeutic monitoring

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CEFTRIAXONE; CIMETIDINE; CORTICOSTEROID; CYTOCHROME P450 2C9; FLUCONAZOLE; LOSARTAN; NAFCILLIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; SULFAMETHOXAZOLE; THIOPENTAL; TICLOPIDINE; WARFARIN;

BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; ENTERIC FEEDING; HEAD INJURY; HUMAN; HYPOALBUMINEMIA; NERVOUS SYSTEM INJURY; NOSE FEEDING; PHARMACOGENETICS; POINT MUTATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN INJURIES; HUMANS; LIVER; PHENYTOIN; PROTEIN BINDING; SEIZURES; TIME FACTORS; TREATMENT OUTCOME;

EID: 37349089336     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318059ae1c     Document Type: Review

References (51)

1. Iudice A, Murri L. Pharmacological prophylaxis of posttraumatic epilepsy. Drugs 2000;59:1091-1099.
2. Pagni CA, Zenga F. Posttraumatic epilepsy with special emphasis on prophylaxis and prevention. Acta Neurochir Suppl 2005;93:27-34.
3. Agrawal A, Timothy J, Pandit L, et al. Post-traumatic epilepsy: an overview. Clin Neurol Neurosurg 2006;108:434-439.
4. Beghi E. Overview of studies to prevent posttraumatic epilepsy. Epilepsia 2003;44(Suppl 10):21-26.
5. Chang B, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60(1):10-16.
6. Foundation TBT. Role of antiseizure prophylaxis following head injury. J Neurotrauma 2000;17:549-553.
7. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomised, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323(8):497-502.
8. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-169.
9. Thomas J, ed. Australian Prescription Products Guide. Hawthorn, Victoria, Australia: Australian Pharmaceutical Publishing Company, Ltd; 2001. pp. 2526-2530. Monograph: Phenytoin Injection BP.
10. Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury; clinical relevance. Clin Pharmacokinet 1998;35(3):209-221.
11. Kitchen D, Smith D. Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding. Seizure 2001;10:265-268.
12. North JB, Penhall JK, Hanieh A, et al. Phenytoin and postoperative epilepsy: a double blind study. J Neurosurg 1983;58:672-677.
13. Markowsky SJ, Skaar DJ, Christie JM, et al. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury. Ann Pharmacother 1996;30:443-448.
14. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002;24(3):379-385.
15. Boucher BA, Rodman JH, Fabian TC. Disposition of phenytoin in critically ill trauma patients. Clin Pharmacol 1987;6:881-887.
16. Boucher BA, Rodman JH, Jaresko GS, et al. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988;44:675-683.
17. Hunt EA. Phenytoin in traumatic brain injury. Arch Dis Child 2002;86(1):62-63.
18. McKindley DS, Boucher BA, Hess MM, et al. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol 1997;37:129-139.
19. Stowe CD, Lee KR, Storgion SA, et al. Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. J Clin Pharmacol 2000;40:1452-1461.
20. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit 1994;16:139-144.
21. Haltiner AM, Newell DW, Temkin NR, et al. Side effects and mortality associated with use of phenytoin in early posttraumatic seizure prophylaxis. J Neurosurg 1999;91:588-592.
22. Boucher BA, Kuhl DA, Fabian TC, et al. Effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991;50:487-497.
23. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and P4502C19 in the stereoselective metabolism of phenytoin to its major metabolites. Drug Metab Dispos 1996;24(12):1401-1403.
24. Yasumori T, Chen LS, Li QH, et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol 1999;57(11):1297-1303.
25. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin metabolism in Black Beninese population. Pharmacogenet Genomics 2005;15(11):779-786.
26. Engel G, Hoffman U, Hiederman H, et al. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59(6):613-623.
27. Anderson GD. Increases in metabolism of valproate and excretion of 6[beta]-hydroxycortisol in patients with traumatic brain injury. Br J Pharmacol 1996;59:613-623.
28. Anderson KE, Conney AH and Kappas A. Nutrition andoxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate, and protein. Clin Pharmacol Ther 1979;493.
29. Fagan TC, Walle T, Oexmann MJ, et al. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther 1987;41:402-406.
30. Young B, Rapp R, Norton J, et al. Failure of prophylactically administered phenytoin to prevent early posttraumatic seizures. J Neurosurg 1983;58:231-235.
31. Bauer LA, Edwards WA, Dellinger EP, et al. Importance of unbound phenytoin serum concentrations in head trauma patients. J Trauma 1983;23(12):1058-1060.
32. Anderson GD. Decreased plasma protein binding of valproate in patients with acute head trauma. J Clin Pharmacol 1994;37:559-562.
33. Beringer PM, Rho JP. Is routine measurement of free phenytoin concentrations rational? Ther Drug Monit 1995;17:381-382.
34. Anderson GD, Pak C, Doane KW. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminaemia. Ann Pharmacother 1997;31:279-284.
35. Rivey MP. Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury. Brain Inj 1995;9:41-47.
36. Faraji B, Yu P. Serum phenytoin concentrations of patients on gastronomy tube feeding. J Neurosci Nurs 1998;30(1):55-59.
37. Sneed RC, Morgan WT. Interference of oral phenytoin absorption by enteral tube feedings. Arch Med Rehab 1988;69(9):682-684.
38. Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001;4:CD000173.
39. Lander CM, Eadie MJ, Tyrer JH. Interactions between anticonvulsants. Proc Aust Assoc Neurol 1975;12:111-116.
40. Algozzie GJ, Stewart RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med 1981;2:244-245.
41. Frigo GM, Lecchini S, Caravaggi M, et al. Reduction in phenytoin clearance caused by phenytoin. Eur J Clin Pharmacol 1983;25:135-137.
42. Blum RA, Wilton JH, Hilligoss, et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-425.
43. Cadle RM, Zenon GJM, Rodriguez-Banath, et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994;28:191-194.
44. Donahue SR, Flockhart DA, Abernathy DR, et al. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C9. Br Clin Pharmacol Ther 1997;62:572-577.
45. Ahmad S. Warfarin Interaction. Arch Intern Med 1990;150:2407.
46. Dasgupta A, Dennen DA, Dean R, et al. Displacement of phenytoin from serum protein carriers by antibiotics: studies with cefriaxone, nafcillin and sulfamethoxazole. Clin Chem 1991;37:98-100.
47. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-439.
48. Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with substrates. Pharmacogenetics 2000;10:95-104.
49. van der Weida J, Steijns LS, van Weelden MJ. The effect of genetic polymorphism of Cytochrome P450 CYP2C9 on phenytoin dose requirements. Pharmacogenetics 2001;11:287-291.
50. Soga Y, Nishimura F, Ohtsuka Y, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic patients. Life Sci 2004;74:827-834.
51. Brandolese R, Scorda MG, Spina E, et al. Severe phenytoin intoxication in a patient homozygous for CYP2C9*3. Clin Pharmacol Ther 2001;70:403.